The FDA issued an emergency use authorization (EUA) for convalescent plasma to treat coronavirus disease 2019 (COVID-19); limited transmission of COVID-19 was reported in reopened childcare centers; universal mask mandates could save lives.
Yesterday, the FDA issued an emergency use authorization for convalescent plasma as a treatment for coronavirus disease 2019 (COVID-19), according to STAT. Convalescent plasma, which is blood plasma derived from patients who have recovered from COVID-19, was touted by President Donald Trump’s press secretary as a major therapeutic breakthrough. However, the lack of confirmed clinical efficacy has drawn some skepticism among the scientific community, as current data suggest the therapy may not be effective for all patient populations.
According to a study conducted by the CDC that examined 666 reopened childcare centers this summer in Rhode Island, limited transmission of COVID-19 was reported among children and staff, which may inform decisions to reopen schools for in-person learning this fall. Reported by CIDRAP, CDC director Robert Redfield, MD, highlighted the significance of these findings, especially in areas with low cases of COVID-19 like Rhode Island. Redfield stressed that for schools to reopen safely, Americans must adhere to mask wearing, social distancing guidelines, and hand hygiene.
According to a projection by the University of Washington's Institute for Health Metrics and Evaluation (IHME), 70,000 lives can be saved by December if the United States issues universal mask mandates. Reported by The Hill, the study estimated that 134,000 Americans could die from COVID-19 by December if safety measures remain stagnant, and the projected death toll could rise if these measures are further laxed. Moreover, IHME predicts that if mask mandates remain the same, COVID-19 death rates would dip in September and increase later in the fall, totaling nearly 310,000 deaths by December 1, 2020. So far, the United States has reported 5.6 million cases of COVID-19 and more than 176,000 deaths.
Urticaria Diagnosis Challenged by Overlapping Pruritic Skin Conditions
April 23rd 2025Urticaria is complicated to diagnose by its symptomatic overlap with other skin conditions and the frequent misclassification in literature of distinct pathologies like vasculitic urticaria and bullous pemphigus.
Read More
New Research Challenges Assumptions About Hospital-Physician Integration, Medicare Patient Mix
April 22nd 2025On this episode of Managed Care Cast, Brady Post, PhD, lead author of a study published in the April 2025 issue of The American Journal of Managed Care®, challenges the claim that hospital-employed physicians serve a more complex patient mix.
Listen
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
ACOs’ Focus on Rooting Out Fraud Aligns With CMS Vision Under Oz
April 23rd 2025Accountable care organizations (ACOs) are increasingly playing the role of data sleuths as they identify and report trends of anomalous billing in hopes of salvaging their shared savings. This mission dovetails with that of CMS, which under the new administration plans to prioritize rooting out fraud, waste, and abuse.
Read More